Groom, K.M. and David, A.L. (2018) The Role of Aspirin, Heparin, and Other Interventions in the Prevention and Treatment of Fetal Growth Restriction. American Journal of Obstetrics and Gynecology, 218, S829-S840.
https://doi.org/10.1016/j.ajog.2017.11.565

has been cited by the following article:

• TITLE: Perinatal Morbidity, Mortality, and Neurodevelopmental Outcomes of Neonates with Fetal Growth Restriction

  AUTHORS: Natsuki Tamashiro, Shuko Chinen, Yoshino Kinjyo, Yukiko Chinen, Tadatsugu Kinjo, Keiko Mekaru

  KEYWORDS: Fetal Death, Fetal Growth Retardation, Neurodevelopmental Disorders, Perinatal Mortality, Umbilical Artery Doppler Velocimetry

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.14 No.3, March 8, 2024

  ABSTRACT: Objective: This study aimed to assess perinatal morbidity, mortality rates, and neurodevelopmental outcomes in the management of fetal growth restriction (FGR) at a single tertiary institute. Methods: Among 2465 deliveries between 2013 and 2019, 109 cases of FGR were reviewed retrospectively for causes, indications for pregnancy termination, perinatal death, overall neonatal outcomes, and long-term prognosis. Results: Excluding FGR due to congenital anomalies (n = 17), the mortality rate was 3.3% (3/92). One neonate delivered at 23 weeks developed cerebral palsy (1.1%). Retinopathy of prematurity occurred in four neonates (4.3%). Neurodevelopmental disorders were present in six neonates (6.5%), all of whom were delivered at 32 - 38 weeks. Significantly lower gestational age at delivery, lower birth weight, and higher umbilical artery resistance indices were observed in neonates with neurodevelopmental disorders. Conclusions: Intact survival before 27 weeks of gestation at delivery with FGR is uncommon. Neurodevelopmental disorders may still develop after delivery at 32 - 38 weeks; consideration should be given to the timing of delivery usingfetal ductus venosus Doppler waveforms measurements to reduce neurodevelopmental disorders.